Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincistrine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects > or = 60 Years old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincistrine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects > or = 60 Years old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vincristine (Primary) ; Antineoplastics
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms HALLMARQ
  • Sponsors Spectrum Pharmaceuticals

Most Recent Events

  • 08 Dec 2015 Results(n=26) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
  • 26 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 16 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top